PDP-716
Generic name: brimonidine tartrate
Treatment for: Glaucoma, Open Angle, Glaucoma/Intraocular Hypertension
Visiox Pharma Announces FDA Acceptance of New Drug Application for Glaucoma
TARRYTOWN, N.Y., Dec. 8, 2022 /PRNewswire/ -- Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency has completed its filing review and accepted for filing the New Drug Application (NDA) for PDP-716 (0.35% brimonidine tartrate) for the treatment of glaucoma.
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 4, 2023.
"The NDA acceptance for filing is an exciting milestone and an important next step towards the planned approval and commercial launch of PDP-716," said Ryan Bleeks, Chief Executive Officer. "If approved, Visiox has the potential to bring the first once-daily brimonidine to market for the treatment of glaucoma to patients and eye care professionals."
Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Each day is an opportunity for us to disrupt and revolutionize the current market to maximize patient and physician satisfaction. As an agile business partner, we will achieve this through a high level of collaboration with all eye care professionals.
Visiox plans to soon submit a second New Drug Application for SDN-037 to the U.S. FDA to address an unmet need for cataract surgery. SDN-037 is a twice daily topical difluprednate corticosteroid utilizing patented TJMTM (Tight Junction Modulation) proprietary formulation. The novel technology provides powerful post-surgical control of inflammation in a clear solution enabling convenient dosing with a proven active ingredient. Cataract extraction is the most frequently performed eye surgery in the U.S. It accounts for 70% of all ocular surgeries. 50 million people are projected to have cataracts in the U.S. by 20501.
PDP-716, SDN-037, and TearActTM delivery technology were licensed by Visiox from Sun Pharma Advanced Research Company Ltd. For more information, please visit Visiox Pharma or LinkedIn.
1. Ocular Surgery Procedures: Market Scope, 2019
SOURCE Visiox Pharma LLC
Posted: December 2022
Related articles
- FDA Issues Complete Response Letter for PDP-716 NDA Due to Inspection Findings at Third-Party API Manufacturing Facility - July 13, 2023
- Visiox Pharma Submits New Drug Application Seeking Approval for First Once-Daily Brimonidine for Glaucoma - October 6, 2022
PDP-716 (brimonidine tartrate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.